Literature DB >> 31275817

Effect of paeoniflorin on cardiac remodeling in chronic heart failure rats through the transforming growth factor β1/Smad signaling pathway.

Mao Liu1,2, Jiao Ai2, Jie Feng1,2, Jiankang Zheng1,2, Kai Tang2, Zhuang Shuai2, Jingxi Yang1,2.   

Abstract

BACKGROUND: Cardiac remodeling is an important mechanism for the occurrence and development of chronic heart failure (CHF). Paeoniflorin (Pae) is the main active ingredient of Chinese herbaceous peony and has novel anti-inflammatory effect. This study was conducted to assess the effects and mechanisms of Pae on cardiac remodeling in CHF rats.
METHODS: A cardiac remodeling rat model was induced by isoprenaline (Iso). Pae (20 µg/kg/d) was administrated to CHF rats for six weeks. Cardiac ultrasound was used to assess the structure and function of CHF rats. Collagen volume fraction (CVF) and perivascular collagen volume area of myocardial tissues were calculated. With real-time polymerase chain reaction and Western blot, the protein and mRNA levels of transforming growth factor β1 (TGF-β1) and Smad3 were detected.
RESULTS: Compared to Iso group, Pae can alleviate cardiac remodeling and improve cardiac function in CHF rats. The levels of CVF and perivascular collagen volume area reduced in Pae group (P<0.05). The expression of TGF-β1 and Smad3 protein decreased in Pae and Cap group (P<0.05). Further, the expression of TGF-β1 and Smad3 mRNA also decreased markedly in the Pae group (P<0.05).
CONCLUSIONS: Pae could attenuate cardiac remodeling and improve cardiac function in CHF rats. The potential mechanism for the cardioprotective effect of Pae may be highly associated with the down-regulating of TGF-β1/Smad signaling pathway.

Entities:  

Keywords:  Chronic heart failure (CHF); cardiac remodeling; paeoniflorin (Pae); samd3; transforming growth factor β1 (TGF-β1)

Year:  2019        PMID: 31275817      PMCID: PMC6603499          DOI: 10.21037/cdt.2019.06.01

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  21 in total

Review 1.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

2.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2016-05-20       Impact factor: 15.534

3.  Paeoniflorin attenuates pressure overload-induced cardiac remodeling via inhibition of TGFβ/Smads and NF-κB pathways.

Authors:  Heng Zhou; He-Xin Yang; Yuan Yuan; Wei Deng; Jie-Yu Zhang; Zhou-Yan Bian; Jing Zong; Jia Dai; Qi-Zhu Tang
Journal:  J Mol Histol       Date:  2013-02-17       Impact factor: 2.611

4.  Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway.

Authors:  Yanling Zhao; Xiao Ma; Jiabo Wang; Yun Zhu; Ruisheng Li; Jian Wang; Xuan He; Limei Shan; Ruilin Wang; Lifu Wang; Yonggang Li; Xiaohe Xiao
Journal:  Fitoterapia       Date:  2014-10-16       Impact factor: 2.882

5.  Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy.

Authors:  Su-Yang Yu; Lei Liu; Pu Li; Jie Li
Journal:  Thorac Cardiovasc Surg       Date:  2012-06-08       Impact factor: 1.827

6.  Triptolide alleviates isoprenaline-induced cardiac remodeling in rats via TGF-β1/Smad3 and p38 MAPK signaling pathway.

Authors:  Mao Liu; Jian Chen; Yongquan Huang; Jianting Ke; Lingling Li; Dan Huang; Wei Wu
Journal:  Pharmazie       Date:  2015-04       Impact factor: 1.267

Review 7.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

8.  Paeoniflorin suppresses TGF-β mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway.

Authors:  Yu Ji; Yan-Nong Dou; Qian-Wen Zhao; Ji-Zhou Zhang; Yan Yang; Ting Wang; Yu-Feng Xia; Yue Dai; Zhi-Feng Wei
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 9.  The pathogenesis of cardiac fibrosis.

Authors:  Ping Kong; Panagiota Christia; Nikolaos G Frangogiannis
Journal:  Cell Mol Life Sci       Date:  2013-05-07       Impact factor: 9.261

10.  Paeoniflorin, the main active constituent of Paeonia lactiflora roots, attenuates bleomycin-induced pulmonary fibrosis in mice by suppressing the synthesis of type I collagen.

Authors:  Yu Ji; Ting Wang; Zhi-Feng Wei; Guo-Xun Lu; Si-de Jiang; Yu-Feng Xia; Yue Dai
Journal:  J Ethnopharmacol       Date:  2013-08-22       Impact factor: 4.360

View more
  3 in total

1.  Endostatin attenuates heart failure via inhibiting reactive oxygen species in myocardial infarction rats.

Authors:  Xuguang Xu; Tingbo Jiang; Yong Li; Liusha Kong
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

Review 2.  Effects and Mechanisms of Taohong Siwu Decoction on the Prevention and Treatment of Myocardial Injury.

Authors:  Chang-Le Shao; Guo-Hong Cui; Hai-Dong Guo
Journal:  Front Pharmacol       Date:  2022-01-26       Impact factor: 5.810

3.  Mechanism of Zhen Wu Decoction in the Treatment of Heart Failure Based on Network Pharmacology and Molecular Docking.

Authors:  Chen-Yu Ma; Yu-Qian Ma; Min Deng
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-15       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.